SERCA2a: its role in the development of heart failure and as a potential therapeutic target

References

• Bers DM. Excitation – Contraction Coupling and Cardiac Contractile Force. 2nd ed. Boston, MA: Kluwer Academic Publishers; 2001.
   Google Scholar
• Bers DM. Cardiac excitation – contraction coupling. Nature. 2002; 415(6868):198–205.
   PubMed Web of Science ®Google Scholar
• Bers DM. Calcium cycling and signaling in cardiac myocytes. Annu Rev Physiol. 2008;70:23–49.
   PubMed Web of Science ®Google Scholar
• Yano K, Zarain-Herzberg A. Sarcoplasmic reticulum calsequestrins: structural and functional properties. Mol Cell Biochem. 1994;135(1):61–70.
   PubMed Web of Science ®Google Scholar
• Beard NA, Laver DR, Dulhunty AF. Calsequestrin and the calcium release channel of skeletal and cardiac muscle. Prog Biophys Mol Biol. 2004;85(1):33–69.
   Web of Science ®Google Scholar
• Beard NA, Wei L, Dulhunty AF. Control of muscle ryanodine receptor calcium release channels by proteins in the sarcoplasmic reticulum lumen. Clin Exp Pharmacol Physiol. 2009;36(3):340–345.
   Web of Science ®Google Scholar
• Bernardo BC, Weeks KL, Pretorius L, McMullen JR. Molecular distinction between physiological and pathological cardiac hypertrophy: experimental findings and therapeutic strategies. Pharmacol Ther. 2010;128(1):191–227.
   PubMed Web of Science ®Google Scholar
• Anwar A, Taimor G, Korkusuz H, et al. PKC-independent signal transduction pathways increase SERCA2 expression in adult rat cardiomyocytes. J Mol Cell Cardiol. 2005;39(6):911–919.
   Web of Science ®Google Scholar
• Arai M, Suzuki T, Nagai R. Sarcoplasmic reticulum genes are upregulated in mild cardiac hypertrophy but downregulated in severe cardiac hypertrophy induced by pressure overload. J Mol Cell Cardiol. 1996;28(8):1583–1590.
   Web of Science ®Google Scholar
• Reyes-Juarez JL, Zarain-Herzberg A. El retículo sarcoplásmico, su función y su papel en las enfermedades cardiacas. [Function and role of the sarcoplasmic reticulum in heart disease]. Arch Cardiol Mex. 2006; 76(Suppl 4):S18–S32. Spanish.
   Google Scholar
• Alpert NR, Brosseau C, Federico A, Krenz M, Robbins J, Warshaw DM. Molecular mechanics of mouse cardiac myosin isoforms. Am J Physiol. 2002;283(4):H1446–H1454.
   Google Scholar
• Vannier C, Chevassus H, Vassort G. Ca-dependence of isometric force kinetics in single skinned ventricular cardiomyocytes from rats. Cardiovasc Res. 1996;32(3):580–586.
   Web of Science ®Google Scholar
• Baker AJ, Figueredo VM, Keung EC, Camacho SA. Ca2+ regulates the kinetics of tension development in intact cardiac muscle. Am J Physiol. 1998;275(3 Pt 2):H744–H750.
   Google Scholar
• Palmer S, Kentish JC. Roles of Ca2+ and crossbridge kinetics in determining the maximum rates of Ca2+ activation and rela-xation in rat and guinea pig skinned trabeculae. Circ Res. 1998;83(2):179–186.
   Web of Science ®Google Scholar
• Teucher N, Prestle J, Seidler T, et al. Excessive sarcoplasmic/endoplasmic reticulum Ca2+-ATPase expression causes increased sarcoplasmic reticulum Ca2+ uptake but decreases myocyte shortening. Circulation. 2004;110(23):3553–3559.
   Web of Science ®Google Scholar
• Bassani JW, Qi M, Samarel AM, Bers DM. Contractile arrest increases sarcoplasmic reticulum calcium uptake and SERCA2 gene expression in cultured neonatal rat heart cells. Circ Res. 1994;74(5):991–997.
   Web of Science ®Google Scholar
• Kaprielian R, del Monte F, Hajjar RJ. Targeting Ca2+ cycling proteins and the action potential in heart failure by gene transfer. Basic Res Cardiol. 2002;97(Suppl 1):I136–I145.
   PubMedGoogle Scholar
• Soltis AR, Saucerman JJ. Synergy between CaMKII substrates and β-adrenergic signaling in regulation of cardiac myocyte Ca(2+) handling. Biophys J. 2010;99(7):2038–2047.
   Web of Science ®Google Scholar
• Zhang T, Johnson EN, Gu Y, et al. The cardiac-specific nuclear delta(B) isoform of Ca2+/calmodulin-dependent protein kinase II induces hypertrophy and dilated cardiomyopathy associated with increased protein phosphatase 2A activity. J Biol Chem. 2002;277(2):1261–1267.
   Web of Science ®Google Scholar
• Backs J, Backs T, Neef S, et al. The delta isoform of CaM kinase II is required for pathological cardiac hypertrophy and remodeling after pressure overload. Proc Natl Acad Sci U S A. 2009;106(7):2342–2347.
   PubMed Web of Science ®Google Scholar
• Tada M, Kirchberger MA, Repke DI, Katz AM. The stimulation of calcium transport in cardiac sarcoplasmic reticulum by adenosine 3′:5′-monophosphate-dependent protein kinase. J Biol Chem. 1974;249(19):6174–6180.
   Web of Science ®Google Scholar
• Katz S, Richter B, Eibschutz B. Characterization of calmodulin-dependent and cyclic-AMP-dependent protein kinase stimulation of cardiac sarcoplasmic reticulum calcium transport. Adv Myocardiol. 1985;6:233–247.
   Google Scholar
• Hoshijima M, Knoll R, Pashmforoush M, Chien K. Reversal of calcium cycling defects in advanced heart failure toward molecular therapy. J Am Coll Cardiol. 2006;48(9 Suppl 1):A15–A23.
   PubMed Web of Science ®Google Scholar
• Chu G, Li L, Sato Y, et al. Pentameric assembly of phospholamban facilitates inhibition of cardiac function in vivo. J Biol Chem. 1998;273(50):33674–33680.
   Web of Science ®Google Scholar
• Negash S, Yao Q, Sun H, Li J, Bigelow DJ, Squier TC. Phospholamban remains associated with the Ca2+- and Mg2+-dependent ATPase following phosphorylation by cAMP-dependent protein kinase. Biochem J. 2000;351(Pt 1):195–205.
   Google Scholar
• Bidwell P, Blackwell DJ, Hou Z, Zima AV, Robia SL. Phospholamban binds with differential affinity to calcium pump conformers. J Biol Chem. 2011;286(40):35044–35050.
   Web of Science ®Google Scholar
• Reiken S, Gaburjakova M, Guatimosim S, et al. Protein kinase A phosphorylation of the cardiac calcium release channel (ryanodine receptor) in normal and failing hearts. Role of phosphatases and response to isoproterenol. J Biol Chem. 2003;278(1):444–453.
   PubMed Web of Science ®Google Scholar
• Huang FL, Glinsmann WH. Separation and characterization of two phosphorylase phosphatase inhibitors from rabbit skeletal muscle. Eur J Biochem. 1976;70(2):419–426.
   Google Scholar
• Nimmo GA, Cohen P. The regulation of glycogen metabolism. Purification and characterisation of protein phosphatase inhibitor-1 from rabbit skeletal muscle. Eur J Biochem. 1978;87(2):341–351.
   Google Scholar
• Braunwald E, Bristow MR. Congestive heart failure: 50 years of progress. Circulation. 2000;102(Suppl 4):IV14–IV23.
   Google Scholar
• Lehnart SE, Wehrens XH, Reiken S, et al. Phosphodiesterase 4D deficiency in the ryanodine-receptor complex promotes heart failure and arrhythmias. Cell. 2005;123(1):25–35.
   PubMed Web of Science ®Google Scholar
• Marx SO, Reiken S, Hisamatsu Y, et al. PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): defective regulation in failing hearts. Cell. 2000;101(4):365–376.
   PubMed Web of Science ®Google Scholar
• Ai X, Curran JW, Shannon TR, Bers DM, Pogwizd SM. Ca2+/calmodulin-dependent protein kinase modulates cardiac ryanodine receptor phosphorylation and sarcoplasmic reticulum Ca2+ leak in heart failure. Circ Res. 2005;97(12):1314–1322.
   Web of Science ®Google Scholar
• Nagai R, Zarain-Herzberg A, Brandl CJ, et al. Regulation of myocardial Ca2+-ATPase and phospholamban mRNA expression in response to pressure overload and thyroid hormone. Proc Natl Acad Sci U S A. 1989;86(8):2966–2970.
   PubMed Web of Science ®Google Scholar
• Zarain-Herzberg A, Fragoso-Medina J, Estrada-Aviles R. Calcium-regulated transcriptional pathways in the normal and pathologic heart. IUBMB Life. 2011;63(10):847–855.
   Web of Science ®Google Scholar
• Prasad AM, Inesi G. Silencing calcineurin A subunit reduces SERCA2 expression in cardiac myocytes. Am J Physiol Heart Circ Physiol. 2011;300(1):H173–H180.
   Web of Science ®Google Scholar
• Prasad AM, Inesi G. Regulation and rate limiting mechanisms of Ca2+ ATPase (SERCA2) expression in cardiac myocytes. Mol Cell Biochem. 2012;361(1–2):85–96.
   Web of Science ®Google Scholar
• Rocchetti M, Besana A, Mostacciuolo G, et al. Modulation of sarcoplasmic reticulum function by Na+/K+ pump inhibitors with different toxicity: digoxin and PST2744 ([E,Z]-3-[[2-aminoethoxy]imino]androstane-6,17-dione hydrochloride). J Pharmacol Exp Ther. 2005;313(1):207–215.
   Web of Science ®Google Scholar
• Micheletti R, Mattera GG, Rocchetti M, et al. Pharmacological profile of the novel inotropic agent (E,Z)-3-([2-aminoethoxy]imino)androstane-6,17-dione hydrochloride (PST2744). J Pharmacol Exp Ther. 2002;303(2):592–600.
   Web of Science ®Google Scholar
• Micheletti R, Palazzo F, Barassi P, et al. Istaroxime, a stimulator of sarcoplasmic reticulum calcium adenosine triphosphatase isoform 2a activity, as a novel therapeutic approach to heart failure. Am J Cardiol. 2007;99(2A):24A–32A.
   PubMed Web of Science ®Google Scholar
• Mattera GG, Lo Giudice P, Loi FM, et al. Istaroxime: a new luso-inotropic agent for heart failure. Am J Cardiol. 2007;99(2A):33A–40A.
   Web of Science ®Google Scholar
• Sabbah HN, Imai M, Cowart D, Amato A, Carminati P, Gheorghiade M. Hemodynamic properties of a new-generation positive luso-inotropic agent for the acute treatment of advanced heart failure. Am J Cardiol. 2007;99(2A):41A–46A.
   Web of Science ®Google Scholar
• Shah SJ, Blair JE, Filippatos GS, et al. Effects of istaroxime on diastolic stiffness in acute heart failure syndromes: results from the Hemodynamic, Echocardiographic, and Neurohormonal Effects of Istaroxime, a Novel Intravenous Inotropic and Lusitropic Agent: a Randomized Controlled Trial in Patients Hospitalized with Heart Failure (HORIZON-HF) trial. Am Heart J. 2009;157(6):1035–1041.
   PubMed Web of Science ®Google Scholar
• Ferrandi M, Barassi P, Tadini-Buoninsegni F, et al. Istaroxime stimulates SERCA2a and accelerates calcium cycling in heart failure by relieving phospholamban inhibition. Br J Pharmacol. 2013;169(8):1849–1861.
   PubMed Web of Science ®Google Scholar
• Gobbini M, Armaroli S, Banfi L, et al. Novel analogues of istaroxime, a potent inhibitor of Na+, K+-ATPase: synthesis and structure–activity relationship. J Med Chem. 2008;51(15):4601–4608.
   Web of Science ®Google Scholar
• Gobbini M, Armaroli S, Banfi L, et al. Novel analogues of istaroxime, a potent inhibitor of Na(+), K(+)-ATPase: synthesis, structure–activity relationship and 3D-quantitative structure-activity relationship of derivatives at position 6 on the androstane scaffold. Bioorg Med Chem. 2010;18(12):4275–4299.
   Web of Science ®Google Scholar
• Cornea RL, Gruber SJ, Lockamy EL, et al. High-throughput FRET assay yields allosteric SERCA activators. J Biomol Screen. 2013;18(1):97–107.
   Google Scholar
• Koitabashi N, Arai M, Tomaru K, et al. Carvedilol effectively blocks oxidative stress-mediated downregulation of sarcoplasmic reticulum Ca2+-ATPase 2 gene transcription through modification of Sp1 binding. Biochem Biophys Res Commun. 2005;328(1):116–124.
   PubMed Web of Science ®Google Scholar
• Hong-Li S, Lei L, Lei S, et al. Cardioprotective effects and underlying mechanisms of oxymatrine against ischemic myocardial injuries of rats. Phytother Res. 2008;22(7):985–989.
   PubMed Web of Science ®Google Scholar
• Cao YG, Jing S, Li L, et al. Antiarrhythmic effects and ionic mechanisms of oxymatrine from Sophora flavescens. Phytother Res. 2010;24(12):1844–1849.
   Web of Science ®Google Scholar
• Shen XC, Yang YP, Xiao TT, Peng J, Liu XD. Protective effect of oxymatrine on myocardial fibrosis induced by acute myocardial infarction in rats involved in TGF-β1-Smads signal pathway. J Asian Nat Prod Res. 2011;13(3):215–224.
   PubMed Web of Science ®Google Scholar
• Huang XY, Chen CX. Effect of oxymatrine, the active component from Radix Sophorae flavescentis (Kushen), on ventricular remodeling in spontaneously hypertensive rats. Phytomedicine. 2013;20(3–4):202–212.
   Web of Science ®Google Scholar
• Zhang M, Wang X, Wang X, et al. Oxymatrine protects against myocardial injury via inhibition of JAK2/STAT3 signaling in rat septic shock. Mol Med Rep. 2013;7(4):1293–1299.
   Web of Science ®Google Scholar
• Wu CK, Lee JK, Chiang FT, et al. Plasma levels of tumor necrosis factor-α and interleukin-6 are associated with diastolic heart failure through downregulation of sarcoplasmic reticulum Ca2+ ATPase. Crit Care Med. 2011;39(5):984–992.
   Web of Science ®Google Scholar
• Hu ST, Tang Y, Shen YF, et al. Protective effect of oxymatrine on chronic rat heart failure. J Physiol Sci. 2011;61(5):363–372.
   Web of Science ®Google Scholar
• Zhang Y, Dong Z, Jin L, et al. Arsenic trioxide-induced hERG K(+) channel deficiency can be rescued by matrine and oxymatrine through up-regulating transcription factor Sp1 expression. Biochem Pharmacol. 2013;85(1):59–68.
   Web of Science ®Google Scholar
• Davia K, Bernobich E, Ranu HK, et al. SERCA2A overexpression decreases the incidence of aftercontractions in adult rabbit ventricular myocytes. J Mol Cell Cardiol. 2001;33(5):1005–1015.
   PubMed Web of Science ®Google Scholar
• del Monte F, Harding SE, Schmidt U, et al. Restoration of contractile function in isolated cardiomyocytes from failing human hearts by gene transfer of SERCA2a. Circulation. 1999;100(23):2308–2311.
   PubMed Web of Science ®Google Scholar
• Hajjar RJ, Kang JX, Gwathmey JK, Rosenzweig A. Physiological effects of adenoviral gene transfer of sarcoplasmic reticulum calcium ATPase in isolated rat myocytes. Circulation. 1997;95(2):423–429.
   Web of Science ®Google Scholar
• He H, Giordano FJ, Hilal-Dandan R, et al. Overexpression of the rat sarcoplasmic reticulum Ca2+ ATPase gene in the heart of transgenic mice accelerates calcium transients and cardiac relaxation. J Clin Invest. 1997;100(2):380–389.
   Web of Science ®Google Scholar
• Niwano K, Arai M, Koitabashi N, et al. Lentiviral vector-mediated SERCA2 gene transfer protects against heart failure and left ventricular remodeling after myocardial infarction in rats. Mol Ther. 2008;16(6):1026–1032.
   Web of Science ®Google Scholar
• Celladon Corporation. Efficacy and Safety Study of Genetically Targeted Enzyme Replacement Therapy for Advanced Heart Failure. Available from http://clinicaltrials.gov/ct2/show/study/NCT00454818. Accessed January 9, 2014.
   Google Scholar
• Jaski BE, Jessup ML, Mancini DM, et al. Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID trial), a first-in-human Phase I/II clinical trial. J Card Fail. 2009;15(3):171–181.
   PubMed Web of Science ®Google Scholar
• Hajjar RJ, Zsebo K, Deckelbaum L, et al. Design of a Phase I/II trial of intracoronary administration of AAV1/SERCA2a in patients with heart failure. J Card Fail. 2008;14(5):355–367.
   PubMed Web of Science ®Google Scholar
• Jessup M, Greenberg B, Mancini D, et al. Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): a Phase II trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure. Circulation. 2011;124(3):304–313.
   PubMed Web of Science ®Google Scholar
• Zsebo KM, Yaroshinsky A, Rudy JJ, et al. Long term effects of AAV1/SERCA2a gene transfer in patients with severe heart failure: analysis of recurrent cardiovascular events and mortality. Circ Res. Epub September 24, 2013.
   Google Scholar
• Celladon Corporation. A Study of Genetically Targeted Enzyme Replacement Therapy for Advanced Heart Failure (CUPID-2b). Available from http://clinicaltrials.gov/ct2/show/record/NCT01643330. Accessed January 9, 2014.
   Google Scholar
• Assistance Publique - Hôpitaux de Paris. AAV1-CMV-Serca2a GENe Therapy Trial in Heart Failure (AGENT-HF). Available from: http://clinicaltrials.gov/ct2/show/NCT01966887. Accessed January 9, 2014.
   Google Scholar
• Imperial College London. The recruitment status of this study is unknown because the information has not been verified recently. Available from: http://clinicaltrials.gov/show/NCT00534703. Accessed January 9, 2014.
   Google Scholar
• Kalyanasundaram A, Lacombe VA, Belevych AE, et al. Up-regulation of sarcoplasmic reticulum Ca(2+) uptake leads to cardiac hypertrophy, contractile dysfunction and early mortality in mice deficient in CASQ2. Cardiovasc Res. 2013;98(2):297–306.
   Web of Science ®Google Scholar
• Nowak KJ, Davies KE. Duchenne muscular dystrophy and dystrophin: pathogenesis and opportunities for treatment. EMBO Rep. 2004;5(9):872–876.
   PubMed Web of Science ®Google Scholar
• Shin JH, Bostick B, Yue Y, Hajjar R, Duan D. SERCA2a gene transfer improves electrocardiographic performance in aged mdx mice. J Transl Med. 2011;9:132.
   PubMed Web of Science ®Google Scholar
• Goonasekera SA, Lam CK, Millay DP, et al. Mitigation of muscular dystrophy in mice by SERCA overexpression in skeletal muscle. J Clin Invest. 2011;121(3):1044–1052.
   Web of Science ®Google Scholar
• Vandecaetsbeek I, Raeymaekers L, Wuytack F, Vangheluwe P. Factors controlling the activity of the SERCA2a pump in the normal and failing heart. Biofactors. 2009;35(6):484–499.
   PubMed Web of Science ®Google Scholar
• Brini M, Carafoli E. Calcium pumps in health and disease. Physiol Rev. 2009;89(4):1341–1378.
   PubMed Web of Science ®Google Scholar
• Gruber SJ, Haydon S, Thomas DD. Phospholamban mutants compete with wild type for SERCA binding in living cells. Biochem Biophys Res Commun. 2012;420(2):236–240.
   Web of Science ®Google Scholar
• Zhang T, Guo T, Mishra S, et al. Phospholamban ablation rescues sarcoplasmic reticulum Ca(2+) handling but exacerbates cardiac dysfunction in CaMKIIδ(C) transgenic mice. Circ Res. 2010;106(2):354–362.
   Web of Science ®Google Scholar
• Kho C, Lee A, Jeong D, et al. SUMO1-dependent modulation of SERCA2a in heart failure. Nature. 2011;477(7366):601–605.
   PubMed Web of Science ®Google Scholar
• Costa MW, Lee S, Furtado MB, et al. Complex SUMO-1 regulation of cardiac transcription factor Nkx2-5. PLoS One. 2011;6(9):e24812.
   Web of Science ®Google Scholar
• Choudhary C, Kumar C, Gnad F, et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science. 2009;325(5942):834–840.
   PubMed Web of Science ®Google Scholar
• Foster DB, Liu T, Rucker J, et al. The cardiac acetyl-lysine proteome. PLoS One. 2013;8(7):e67513.
   PubMed Web of Science ®Google Scholar
• Sundaresan NR, Pillai VB, Gupta MP. Emerging roles of SIRT1 deacetylase in regulating cardiomyocyte survival and hypertrophy. J Mol Cell Cardiol. 2011;51(4):614–618.
   PubMed Web of Science ®Google Scholar
• Sulaiman M, Matta MJ, Sunderesan NR, Gupta MP, Periasamy M, Gupta M. Resveratrol, an activator of SIRT1, upregulates sarcoplasmic calcium ATPase and improves cardiac function in diabetic cardiomyopathy. Am J Physiol. 2010;298(3):H833–H843.
   PubMed Web of Science ®Google Scholar
• Rimbaud S, Ruiz M, Piquereau J, et al. Resveratrol improves survival, hemodynamics and energetics in a rat model of hypertension leading to heart failure. PLoS One. 2011;6(10):e26391.
   Web of Science ®Google Scholar
• Gupta MP, Samant SA, Smith SH, Shroff SG. HDAC4 and PCAF bind to cardiac sarcomeres and play a role in regulating myofilament contractile activity. J Biol Chem. 2008;283(15):10135–10146.
   PubMed Web of Science ®Google Scholar
• Hossain P, Kawar B, El Nahas M. Obesity and diabetes in the developing world – a growing challenge. N Engl J Med. 2007;356(3):213–215.
   PubMed Web of Science ®Google Scholar
• Relling DP, Esberg LB, Fang CX, et al. High-fat diet-induced juvenile obesity leads to cardiomyocyte dysfunction and upregulation of Foxo3a transcription factor independent of lipotoxicity and apoptosis. J Hypertens. 2006;24(3):549–561.
   PubMed Web of Science ®Google Scholar
• Ouwens DM, Boer C, Fodor M, et al. Cardiac dysfunction induced by high-fat diet is associated with altered myocardial insulin signalling in rats. Diabetologia. 2005;48(6):1229–1237.
   Web of Science ®Google Scholar
• Alves AJ, Ribeiro F, Goldhammer E, et al. Exercise training improves diastolic function in heart failure patients. Med Sci Sports Exerc. 2012;44(5):776–785.
   PubMed Web of Science ®Google Scholar
• de las Fuentes L, Waggoner AD, Mohammed BS, et al. Effect of moderate diet-induced weight loss and weight regain on cardiovascular structure and function. J Am Coll Cardiol. 2009;54(25):2376–2381.
   PubMed Web of Science ®Google Scholar
• Rolim NP, Medeiros A, Rosa KT, et al. Exercise training improves the net balance of cardiac Ca2+ handling protein expression in heart failure. Physiol Genomics. 2007;29(3):246–252.
   Web of Science ®Google Scholar
• Paulino EC, Ferreira JC, Bechara LR, et al. Exercise training and caloric restriction prevent reduction in cardiac Ca2+-handling protein profile in obese rats. Hypertension. 2010;56(4):629–635.
   Web of Science ®Google Scholar
• Assayag P, Charlemagne D, de Leiris J, et al. Senescent heart compared with pressure overload-induced hypertrophy. Hypertension. 1997;29(1 Pt 1):15–21.
   Web of Science ®Google Scholar
• Azhar G, Zhang X, Wang S, Zhong Y, Quick CM, Wei JY. Maintaining serum response factor activity in the older heart equal to that of the young adult is associated with better cardiac response to isoproterenol stress. Basic Res Cardiol. 2007;102(3):233–244.
   Web of Science ®Google Scholar
• Kaplan P, Jurkovicova D, Babusikova E, et al. Effect of aging on the expression of intracellular Ca(2+) transport proteins in a rat heart. Mol Cell Biochem. 2007;301(1–2):219–226.
   Web of Science ®Google Scholar
• Lokuta AJ, Maertz NA, Meethal SV, et al. Increased nitration of sarcoplasmic reticulum Ca2+-ATPase in human heart failure. Circulation. 2005;111(8):988–995.
   Web of Science ®Google Scholar
• Knyushko TV, Sharov VS, Williams TD, Schoneich C, Bigelow DJ. 3-Nitrotyrosine modification of SERCA2a in the aging heart: a distinct signature of the cellular redox environment. Biochemistry. 2005;44(39):13071–13081.
   Web of Science ®Google Scholar
• Adachi T, Weisbrod RM, Pimentel DR, et al. S-glutathiolation by peroxynitrite activates SERCA during arterial relaxation by nitric oxide. Nat Med. 2004;10(11):1200–1207.
   PubMed Web of Science ®Google Scholar
• Berger HJ, Zaret BL, Speroff L, Cohen LS, Wolfson S. Regional cardiac prostaglandin release during myocardial ischemia in anesthetized dogs. Circ Res. 1976;38(6):566–571.
   Web of Science ®Google Scholar
• Lai J, Jin H, Yang R, et al. Prostaglandin F2α induces cardiac myocyte hypertrophy in vitro and cardiac growth in vivo. Am J Physiol. 1996;271(6 Pt 2):H2197–H2208.
   Google Scholar
• Chazov EI, Pomoinetsky VD, Geling NG, Orlova TR, Nekrasova AA, Smirnov VN. Heart adaptation to acute pressure overload: an involvement of endogenous prostaglandins. Circ Res. 1979;45(2):205–211.
   Web of Science ®Google Scholar
• Hara S, Arai M, Tomaru K, et al. Prostaglandin F2α inhibits SERCA2 gene transcription through an induction of Egr-1 in cultured neonatal rat cardiac myocytes. Int Heart J. 2008;49(3):329–342.
   Web of Science ®Google Scholar
• Andrews C, Ho PD, Dillmann WH, Glembotski CC, McDonough PM. The MKK6–p38 MAPK pathway prolongs the cardiac contractile calcium transient, downregulates SERCA2, and activates NF-AT. Cardiovasc Res. 2003;59(1):46–56.
   PubMed Web of Science ®Google Scholar
• Molkentin JD. Calcineurin–NFAT signaling regulates the cardiac hypertrophic response in coordination with the MAPKs. Cardiovasc Res. 2004;63(3):467–475.
   PubMed Web of Science ®Google Scholar
• Scharf M, Neef S, Freund R, et al. Mitogen-activated protein kinase-activated protein kinases 2 and 3 regulate SERCA2a expression and fiber type composition to modulate skeletal muscle and cardiomyocyte function. Mol Cell Biol. 2013;33(13):2586–2602.
   PubMed Web of Science ®Google Scholar
• Rowe GC, Jiang A, Arany Z. PGC-1 coactivators in cardiac development and disease. Circ Res. 2010;107(7):825–838.
   PubMed Web of Science ®Google Scholar
• Kemi OJ, Hoydal MA, Haram PM, et al. Exercise training restores aerobic capacity and energy transfer systems in heart failure treated with losartan. Cardiovasc Res. 2007;76(1):91–99.
   Web of Science ®Google Scholar
• Ngoh GA, Facundo HT, Zafir A, Jones SP. O-GlcNAc signaling in the cardiovascular system. Circ Res. 2010;107(2):171–185.
   Web of Science ®Google Scholar
• Lunde IG, Aronsen JM, Kvaloy H, et al. Cardiac O-GlcNAc signaling is increased in hypertrophy and heart failure. Physiol Genomics. 2012;44(2):162–172.
   Web of Science ®Google Scholar
• Jones SP, Zachara NE, Ngoh GA, et al. Cardioprotection by N-acetylglucosamine linkage to cellular proteins. Circulation. 2008;117(9):1172–1182.
   Web of Science ®Google Scholar
• Ngoh GA, Watson LJ, Facundo HT, Dillmann W, Jones SP. Non-canonical glycosyltransferase modulates post-hypoxic cardiac myocyte death and mitochondrial permeability transition. J Mol Cell Cardiol. 2008;45(2):313–325.
   Web of Science ®Google Scholar
• Hirose K, Tsutsumi YM, Tsutsumi R, et al. Role of the O-linked β-N-acetylglucosamine in the cardioprotection induced by isoflurane. Anesthesiology. 2011;115(5):955–962.
   Web of Science ®Google Scholar
• Lima VV, Giachini FR, Carneiro FS, et al. O-GlcNAcylation contributes to the vascular effects of ET-1 via activation of the RhoA/Rho-kinase pathway. Cardiovasc Res. 2011;89(3):614–622.
   Web of Science ®Google Scholar
• Facundo HT, Brainard RE, Watson LJ, et al. O-GlcNAc signaling is essential for NFAT-mediated transcriptional reprogramming during cardiomyocyte hypertrophy. Am J Physiol Heart Circ Physiol. 2012;302(10):H2122–H2130.
   Web of Science ®Google Scholar
• Sena S, Hu P, Zhang D, et al. Impaired insulin signaling accelerates cardiac mitochondrial dysfunction after myocardial infarction. J Mol Cell Cardiol. 2009;46(6):910–918.
   Web of Science ®Google Scholar
• Domenighetti AA, Danes VR, Curl CL, Favaloro JM, Proietto J, Delbridge LM. Targeted GLUT-4 deficiency in the heart induces cardiomyocyte hypertrophy and impaired contractility linked with Ca(2+) and proton flux dysregulation. J Mol Cell Cardiol. 2010;48(4):663–672.
   Web of Science ®Google Scholar
• Brady M, Koban MU, Dellow KA, Yacoub M, Boheler KR, Fuller SJ. Sp1 and Sp3 transcription factors are required for trans-activation of the human SERCA2 promoter in cardiomyocytes. Cardiovasc Res. 2003;60(2):347–354.
   Web of Science ®Google Scholar
• Takizawa T, Arai M, Tomaru K, et al. Transcription factor Sp1 regulates SERCA2 gene expression in pressure-overloaded hearts: a study using in vivo direct gene transfer into living myocardium. J Mol Cell Cardiol. 2003;35(7):777–783.
   Web of Science ®Google Scholar
• Yang X, Su K, Roos MD, Chang Q, Paterson AJ, Kudlow JE. O-linkage of N-acetylglucosamine to Sp1 activation domain inhibits its transcriptional capability. Proc Natl Acad Sci U S A. 2001;98(12):6611–6616.
   PubMed Web of Science ®Google Scholar
• Hu Y, Belke D, Suarez J, et al. Adenovirus-mediated overexpression of O-GlcNAcase improves contractile function in the diabetic heart. Circ Res. 2005;96(9):1006–1013.
   Web of Science ®Google Scholar
• Cox EJ, Marsh SA. Exercise and diabetes have opposite effects on the assembly and O-GlcNAc modification of the mSin3A/HDAC1/2 complex in the heart. Cardiovasc Diabetol. 2013;12(1):101.
   Google Scholar
• Clark RJ, McDonough PM, Swanson E, et al. Diabetes and the accompanying hyperglycemia impairs cardiomyocyte calcium cycling through increased nuclear O-GlcNAcylation. J Biol Chem. 2003;278(45):44230–44237.
   PubMed Web of Science ®Google Scholar
• Yokoe S, Asahi M, Takeda T, et al. Inhibition of phospholamban phosphorylation by O-GlcNAcylation: implications for diabetic cardiomyopathy. Glycobiology. 2010;20(10):1217–1226.
   Web of Science ®Google Scholar
• Kim HS, Woo JS, Joo HJ, Moon WK. Cardiac transcription factor Nkx2.5 is downregulated under excessive O-GlcNAcylation condition. PLoS One. 2012;7(6):e38053.
   Web of Science ®Google Scholar
• Ikeda S, He A, Kong SW, et al. MicroRNA-1 negatively regulates expression of the hypertrophy-associated calmodulin and Mef2a genes. Mol Cell Biol. 2009;29(8):2193–2204.
   PubMed Web of Science ®Google Scholar
• Li D, He B, Zhang H, et al. The inhibitory effect of miRNA-1 on ET-1 gene expression. FEBS Lett. 2012;586(7):1014–1021.
   Web of Science ®Google Scholar
• Karakikes I, Chaanine AH, Kang S, et al. Therapeutic cardiac-targeted delivery of miR-1 reverses pressure overload-induced cardiac hypertrophy and attenuates pathological remodeling. J Am Heart Assoc. 2013;2(2):e000078.
   Web of Science ®Google Scholar
• Hajjar RJ, Schmidt U, Kang JX, Matsui T, Rosenzweig A. Adenoviral gene transfer of phospholamban in isolated rat cardiomyocytes. Rescue effects by concomitant gene transfer of sarcoplasmic reticulum Ca(2+)-ATPase. Circ Res. 1997;81(2):145–153.
   Web of Science ®Google Scholar
• Most P, Remppis A, Pleger ST, Katus HA, Koch WJ. S100A1: a novel inotropic regulator of cardiac performance. Transition from molecular physiology to pathophysiological relevance. Am J Physiol Regul Integr Comp Physiol. 2007;293(2):R568–R577.
   PubMed Web of Science ®Google Scholar
• Pleger ST, Shan C, Ksienzyk J, et al. Cardiac AAV9-S100A1 gene therapy rescues post-ischemic heart failure in a preclinical large animal model. Sci Transl Med. 2011;3(92):92ra64.
   PubMed Web of Science ®Google Scholar
• Pleger ST, Most P, Boucher M, et al. Stable myocardial-specific AAV6-S100A1 gene therapy results in chronic functional heart failure rescue. Circulation. 2007;115(19):2506–2515.
   PubMed Web of Science ®Google Scholar
• Ritterhoff J, Most P. Targeting S100A1 in heart failure. Gene Ther. 2012;19(6):613–621.
   PubMed Web of Science ®Google Scholar